Berthold DR et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242–245
In 2004, the TAX 327 study investigators reported that high-dose docetaxel given every 2 weeks produced better survival outcomes than did mitoxantrone in men with metastatic hormone-refractory prostate cancer (HRPC). In their updated analysis of this trial, Berthold et al. confirm the survival benefit conferred by docetaxel-based regimens and evaluate survival in various subgroups of patients.
The TAX 327 trial enrolled 1,006 men with progressive metastatic HRPC. All patients received prednisone 5 mg twice daily and were randomly assigned to receive docetaxel 75 mg/m2 administered every 3 weeks for up to 10 cycles (D3P), docetaxel 30 mg/m2 administered weekly for 5 of 6 weeks for up to 5 cycles (D1P), or mitoxantrone 12 mg/m2 every 3 weeks; participants were followed up every 3 weeks.
This analysis found a significant difference in the median survival time of patients on the D3P regimen and those receiving mitoxantrone (19.2 months vs 16.3 months; P = 0.004), which was greater than that found in the 2004 analysis (18.9 months vs 16.5 months; P = 0.009). The difference in survival between patients on D1P and those receiving mitoxantrone was not significant. The survival benefit conferred by D3P was maintained in patients with a greater or lesser disease burden and in the following subgroups: patients with visceral disease; those with substantial pain; individuals with a Karnofsky performance status ≤80%; and those with PSA levels above or below 115 ng/ml. or <115 ng/ml.
The authors conclude that high-dose docetaxel administered every 3 weeks improves survival compared with mitoxantrone in men with HRPC treated with prednisone.
Change history
17 May 2018
This article was published with the same DOI as a previous publication. A new DOI has been assigned and registered at Crossref, and has been corrected in the article.
Rights and permissions
About this article
Cite this article
Docetaxel versus mitoxantrone in men with hormone-refractory prostate cancer. Nat Rev Urol 5, 293 (2008). https://doi.org/10.1038/ncponc1115x
Issue Date:
DOI: https://doi.org/10.1038/ncponc1115x